MedTrace Logo

Date Fruit Effects in Type 2 Diabetes

NCT04616066 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2022-10-04

No results posted yet for this study

Summary

Dried dates (Phoenix dactylifera) have the second highest phytoestrogen content of any fruit, only secondary to dried apricots with 329ug of phytoestrogens per 100g. The date palm is one of oldest planted trees on the earth at around 2,000 years old. Dates are nutritionally rich and a good source of fiber and carbohydrates and their potential medicinal and nutritional effects have been suggested in a number of studies. Date sugars have also been shown to be phenol rich, potent antioxidant, and strong inhibitor of α -glycosidase that may also have benefit in diabetes. In addition, dates are rich in micronutrients that may also have benefit for diabetes and insulin resistance . Dates have a glycemic index of 50 and studies have shown that the consumption of differing varieties of dates do not significantly affect the acute glycemia in patients with type 2 diabetes.

The objective of this study is to investigate the effect of date phytoestrogens on HbA1C and fasting blood glucose in patients with type 2 diabetes in comparison to the same glycemic load of raisins that have low phytoestrogen content.

Conditions

  • Type2 Diabetes

Interventions

OTHER

Dates

The effect of date phytoestrogens on HbA1C and fasting blood glucose in patients with type 2 diabetes

OTHER

Raisins

The effect of raisins phytoestrogens on HbA1C and fasting blood glucose in patients with type 2 diabetes

Sponsors & Collaborators

  • King Hamad University Hospital, Bahrain

    collaborator OTHER

  • Royal College of Surgeons in Ireland - Medical University of Bahrain

    lead OTHER

Principal Investigators

  • Naji Alamuddin, Dr. · Royal College of Surgeons in Ireland - Bahrain

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-10
Primary Completion
2022-04-30
Completion
2022-05-30

Countries

  • Bahrain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04616066 on ClinicalTrials.gov